Largo Clinic 1

Florida Behavioral Medicine

Mania

Depression

Depressive Disorder

Major Depressive Disorder

Bipolar Disorder

Brexpiprazole

ANC-501

Otsuka

Ancora Biotech (EmbarkNeuro)

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This is a single-arm, open-label Phase 2 study to assess the safety, tolerability, pharmacokinetics (PK), and activity of ANC-501 oral capsules as adjunctive treatment in subjects diagnosed with major depressive disorder (MDD)

ANC-501 in the Treatment of Adults With Major Depressive Disorder

Florida Behavioral Medicine | Largo Clinic 1

Site insights

Work at this site?

Active trials

ANC-501 in the Treatment of Adults With Major Depressive Disorder

Trial sponsors